ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2025 Company Presentations
All items marked with an * are mandatory to complete
The maximum number of words for this abstract is 400
Please be sure to complete the following:

Company name-AlonBio LTD---------- * Website- AlonBio@com ---------- *

CEO name-Arnon Aharon ----------* Cell phone number---------- *

CATEGORY: Biotech/Pharma

- Immunology and Inflammation Reclaim top Priorities in BioPharma: Driver and Opportunities

You may delete the section instructions, leaving only the bolded bullet title
Answers below should not exceed 60 words per question:

- Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.
- **BKT300: A Novel Anti-Inflammatory Small Molecule Targeting the Protein Regulator of the Cytokinesis (PRC1) Pathway for Atopic Dermatitis Treatment**
-
- Michal Abraham[1], Hanna Wald[1], Rakefet Rosenfeld[1], Orly Eizenberg[1], Arnon Aharon[1], Amnon Peled[1, 2]
-
- AlonBio Ltd., Ness Ziona, Israel. [1]
- Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, Israel. [2]
-
- BKT300, a small molecule (SM, MW 399.33, C22H25NO6) was identified following phenotypic HTP screening for SMs that inhibit immune cell migration. BKT300 selectively inhibits (in pM range) the in vitro migration of immune cells in response to chemokines by targeting protein regulator of cytokinesis 1 (PRC1). BKT300 treatment disrupts actin and microtubule formation and organization, leading to inhibition of immune cell migration. In vivo, oral, subcutaneous, and topical administration of BKT300 is highly effective in suppressing inflammation in MC903 mouse models of atopic dermatitis (AD). BKT300 had no effect on WBC counts, spleen size, or body weight suggesting a better safety profile compared to the steroid clobetasol. BKT300 exhibited an excellent safety profile when administered at high doses across multiple species, including mice, rats, minipigs, and non-human primates. Notably, treatment with BKT300 had no adverse effects on hematopoiesis or biochemical parameters, even at doses significantly exceeding the effective

therapeutic dose. BKT300 has completed all CMC and toxicology preparations required for a FIH study. As a novel, first-in-class targeted anti-inflammatory drug candidate, BKT300 offers a promising new therapeutic option for the treatment of AD.